Format

Send to

Choose Destination
Lung Cancer. 2015 May;88(2):215-22. doi: 10.1016/j.lungcan.2015.02.011. Epub 2015 Feb 21.

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.

Author information

1
Unité d'Oncologie Thoracique-Pneumologie, CHU de Grenoble, INSERM U823 Grenoble, France. Electronic address: DMoro-Sibilot@chu-grenoble.fr.
2
Vrije Universiteit Medical Centre, Amsterdam, The Netherlands.
3
Hospital Universitario La Paz, Madrid, Spain.
4
Medical University of Gdańsk, Gdynia, Poland.
5
Amphia Hospital Breda, Rotterdam, The Netherlands; Erasmus MC, Rotterdam, The Netherlands.
6
Hospital Costa del Sol, Marbella, Spain.
7
Eli Lilly and Company, Houten, The Netherlands.
8
Eli Lilly and Company, Neuilly-sur-Seine, France.
9
Eli Lilly GmbH, Vienna, Austria.
10
Eli Lilly and Company, Indianapolis, IN, USA.
11
Oy Eli Lilly, Ab, Finland.
12
Pathologisches Institut, Universitätsklinikum, Heidelberg, Germany.

Abstract

INTRODUCTION:

FRAME was a prospective observational study that captured real-world data on patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapies as first-line treatment (FLT) across Europe. As previously reported, most patients observed in the study had initiated FLT with either pemetrexed, gemcitabine, vinorelbine or taxanes in combination with a platinum. Baseline patient and disease characteristics including age, performance status, and histology varied (all p<0.01) across cohorts.

METHODS:

Consenting adult patients initiating FLT for advanced or metastatic NSCLC with platinum-based chemotherapy, with or without a targeted agent, entered the study between April 2009 and February 2011. The choice of FLT was left to physicians' discretion per routine clinical practice. The primary objective was to evaluate overall survival (OS) across platinum-based doublet chemotherapy cohorts and key secondary objectives included the evaluation of OS in patients with different histological subtypes of NSCLC. Survival outcomes were assessed using Kaplan-Meier analysis, and unadjusted estimates are presented.

RESULTS:

Median OS in months was 10.3 across cohorts (n=1524), 10.7 for pemetrexed (n=569), 10.0 for gemcitabine (n=360), 9.1 for taxanes (n=295), and 10.7 for vinorelbine (n=300). For patients with non-squamous NSCLC who received cisplatin (n=616, 40% of total), median OS in months was 10.6 across the cohorts, 11.6 for pemetrexed, 8.4 for gemcitabine, 9.6 for taxanes, and 9.9 for vinorelbine.

CONCLUSIONS:

FRAME describes real-world treatment patterns and survival for patients initiating FLT for advanced or metastatic NSCLC between 2009 and 2011 across Europe.

KEYWORDS:

Health resources; Non-small cell lung cancer (NSCLC); Observational study; Survival

PMID:
25748103
DOI:
10.1016/j.lungcan.2015.02.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center